Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)

Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, Schlaak M, Loquai C, Gutzmer R, Kieker F, Berking C, Bender A, Schneider L, Enk A, Garbe C, Weichenthal M, Schadendorf D, Hauschild A, Mohr P (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 14

Pages Range: 9-9

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Universitätsklinikum Heidelberg DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Elbe Kliniken Stade-Buxtehude DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Köln DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Klinikum der Medizinischen Hochschule Hannover DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE) Universitätsklinikum Ulm DE Germany (DE)

How to cite

APA:

Hassel, J., Forschner, A., Bluhm, L., Heinzerling, L., Zimmer, L., Utikal, J.,... Mohr, P. (2016). Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP). (pp. 9-9).

MLA:

Hassel, J., et al. "Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)." 2016. 9-9.

BibTeX: Download